Darya-Varia Laboratoria Tbk

Overview

DVLA Overview

PT Darya-Varia Laboratoria Tbk (Darya-Varia) is an Indonesia-based company operating in the pharmaceutical industry. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The Company provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The Company also provides Imunped as supplement for kids with Zinc and vitamin C for children.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: DVLA

Development
Market Cap.
IDR 1.76Trillion

~$108.31M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

DVLA Valuation Metrics

1,575

IDR
+1.0%

Closing Price on 2024-07-19

Price to Equity

11.54

P/E

At 11.54x P/E TTM, DVLA.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

1.20

P/B

At 1.20x P/B TTM, DVLA.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.92

P/S

At 0.92x P/S TTM, DVLA.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Darya-Varia Laboratoria Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Darya-Varia Laboratoria Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow8.11x
Price/Forward Earnings-
Enterprise Value/Revenue0.77x
Enterprise Value/EBITDA6.14x
PEG Ratio1.07x

Intrinsic Value

Last closing: IDR1,5752024-07-19
IDR 1,538.13

Fairly Close to Intrinsic Value: Analyst's intrinsic value is of DVLA is IDR1,538, which is 1% lower than DVLA's last closing price of IDR1,575 (as of 2024-07-19).

Valuation Recap of DVLA stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 11.54x is above the ID market average of 8.44x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (10.21x).

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.20x is similar to the peers average of 1.20x in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.92x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of DVLA's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. DVLA's P/CF ratio of 8.11x is considered healthy by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. DVLA's EV/R ratio of 0.77x is considered extremely underpriced by the market. The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.12x.

Medium
Fairly Close to Intrinsic Value: Analyst's intrinsic value is of DVLA is IDR 1,538.13, which is 1% lower than DVLA's last closing price of IDR 1,575.00.

Peers

DVLA Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.62T28.96T 30.94T 2.87T 25.323.24
MIKAPT Mitra Keluarga Karyasehat Tbk.41.17T7.81T 4.48T 0.97T 42.256.74
SILOPT Siloam International Hospitals Tbk.34.40T11.42T 11.56T 0.98T 35.274.35
SRAJSejahteraraya Anugrahjaya Tbk27.60T5.62T 2.71T -0.02T -1387.8514.83
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk22.35T4.25T 3.71T 1.04T 21.475.89
HEALPT Medikaloka Hermina Tbk.19.88T9.20T 6.14T 0.52T 38.274.77
TSPCTempo Scan Pacific Tbk9.02T11.93T 13.33T 1.02T 8.881.11
PRAYPT Famon Awal Bros Sedaya Tbk8.52T4.81T 1.93T 0.21T 41.372.96
SOHOPT Soho Global Health Tbk8.50T5.13T 8.58T 0.44T 19.303.37
KAEFKimia Farma Tbk.3.53T17.34T 10.20T -1.59T -2.220.63
Competitiveness Recap of DVLA stock
WeightNotesScore
High
At a market cap of IDR 1,764.00 billion, DVLA.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 11.54, DVLA.JK ranks 8 out of 10 companies in the Healthcare sector for P/E value. The average PE is -114.42 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Mitra Keluarga Karyasehat Tbk. (42.25) in the Healthcare sector.

Medium
At a PE of 11.54, DVLA.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.21). false

Medium
At a revenue of IDR 1.91 trillion, DVLA.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.15 trillion, DVLA.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of DVLA

Growth Forecasts

Analyst Ratings

Based on ratings from 1 analysts for DVLA over the past 3 months.

Buy

Strong Buy

0.0%

Buy

100.0%

Hold

0.0%

Sell

0.0%

Strong Sell

0.0%

Last Update: 2024-06-28

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.83% against the IDX average of +13.8%.

Pharmaceuticals & Health Care Research sector overview
No data is available for DVLA at the moment.
Future growth prospect of DVLA
WeightNotesScore
High
DVLA's projected growth rate of 14.83% is above the ID market average of 13.82%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.33% in 2025. This number is higher than the previous year 2024's growth rate of 6.68%. This bodes well for DVLA's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 16.41% in 2025. This number is higher than the previous year 2024's EPS growth of 5.49%. This bodes well for DVLA's earnings growth prospects in the next 2 years.

Medium
DVLA and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 17.62% in 2025 while revenue growth is projected to increase by 20.39%. These macroeconomic trends will likely be a tailwind for DVLA's earnings growth prospects in the next 2 years.

Technical

Daily Technical Ratings of DVLA

Oscillators

Buy

Sell

0

Neutral

9

Buy

2

Summary

Buy

Sell

2

Neutral

10

Buy

14

Moving Averages

Strong Buy

Sell

2

Neutral

1

Buy

12

Summary

Technical Ratings of DVLA
IndicatorSummarySellNeutralBuy
SummaryBuy21014
OscillatorsBuy092
Moving AveragesStrong Buy2112

Last Update: 2024-07-19

Loading...
Loading...

Management

Executive Management

President Director

Dr. Ian Martin Wibawa Kloer15.2 years
Angelito Celso Corsame Racho, JrDirector
Yustina Endang SetyowatiDirector
Celso Paz LimDirector
Dennis Tee CoDirector
NamePositionShares%Stock Value
(in Billion IDR)
No data is available for DVLA at the moment.

Ownership

DVLA Ownership

NameNumber of SharesOwnership (%)Value
Blue Sphere Singapore Pte Ltd1,031,737,31292.121,624.99B
Public (Scripless)86,938,4807.77136.93B
Public (Scrip)1,324,2080.112.09B

DVLA Filings

No noteworthy filings to report on

    Sectors, Indonesia's Financial Data Layer

    We hate spam as much as you do. We do not resell your data.

    Email us at sectors@supertype.ai for enquiries on using Sectors for your organization.

    © 2024 Supertype Pte. Ltd.
    (and subsidiary PT. Supertype Teknologi Nusantara)